Study Finds Mannatech’s OsoLean™ Powder May Reduce Waist Circumference and Appetite in Overweight Adults
Results of preliminary study published in “The Open Nutraceuticals Journal”
Coppell, Texas, March 23, 2009 – Mannatech, Incorporated (NASDAQ - MTEX), a leading developer and provider of proprietary dietary supplements, weight management products and skin care solutions, today announced the results of a preliminary study indicating Mannatech’s OsoLean ™ powder, when supplemented with proper diet and exercise, may result in decreased weight, BMI and waist circumference in healthy, overweight adults.*
“We are pleased that this study, which provides further scientific evidence that OsoLean powder can provide significant results in overweight adults striving to maintain a healthy lifestyle, was published,” said Chief Science Officer and Senior Vice President of Mannatech Dr. Robert A. Sinnott , MNS. “Because Mannatech is devoted to developing new wellness technologies with efficacy backed by peer-reviewed human clinical trials, this study is very encouraging.”
This preliminary, open-label, 8-week study of 112 overweight adults, published March 16 in The Open Nutraceuticals Journal demonstrated that daily intake of OsoLean powder appeared to reduce appetite, support weight loss and reduce waist circumference(1).*
After being advised to restrict their daily caloric intake and add the supplement to the beverage of their choice before breakfast and dinner, subjects who participated in the study also completed quality of life questionnaires and reported better appetite control and improved energy levels by the end of the study.*
The study was conducted by Mannatech scientists in collaboration with researchers in the Department of Biostatistics at the University of North Texas Health Science Center in Fort Worth, Texas. To view the study findings, please go to the Peer-Reviewed Science section of www.MannatechScience.org.
In a related 12-week, double-blind, placebo-controlled study published in 2008, consumption of the same peptide blend in OsoLean powder in a flavored, sweetened beverage, in conjunction with a 500-calorie reduced diet, helped to enhance fat loss and retain lean muscle mass when compared to control subjects consuming a placebo in addition to dieting.*
Follow-on studies are being planned to further explore the benefits of OsoLean powder.
*This statement has not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.
Mannatech, Incorporated, is a global wellness solutions provider of innovative, high-quality, proprietary dietary supplements, weight management products and skin care solutions sold through independent Associates and Members located in the United States and the international markets of Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, Germany, South Africa, and Singapore. For more information please visit www.mannatech.com or www.allaboutmannatech.com.
Please Note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into newinternational markets. Although Mannatech believes that the expectations, statements, and assumptions
reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
HCK2 Partners for Mannatech
(972) 716-0500, ext. 41